Literature DB >> 23118231

Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19.

R Leila Reynald1, Stefaan Sansen, C David Stout, Eric F Johnson.   

Abstract

To identify the structural features underlying the distinct substrate and inhibitor profiles of P450 2C19 relative to the closely related human enzymes, P450s 2C8 and 2C9, the atomic structure (Protein Data Bank code 4GQS) of cytochrome P450 2C19 complexed with the inhibitor (2-methyl-1-benzofuran-3-yl)-(4-hydroxy-3,5-dimethylphenyl)methanone (Protein Data Bank chemical component 0XV) was determined to 2.87 Å resolution by x-ray crystallography. The conformation of the peptide backbone of P450 2C19 is most similar to that of P450 2C8, but the substrate-binding cavity of P450 2C8 is much larger than that of P450 2C19 due to differences in the amino acid residues that form the substrate-binding cavities of the two enzymes. In contrast, the substrate-binding cavity of P450 2C19 is much more similar in size to that of the structure of the P450 2C9 flurbiprofen complex than to that of a modified P450 2C9 or that of P450 2C8. The cavities of the P450 2C19 0XV complex and the P450 2C9 flurbiprofen complex differ, however, because the helix B-C loops of the two enzymes are dissimilar. These conformational differences reflect the effects of adjacent structural elements that interact with the B-C loops and that differ between the two enzymes. The availability of a structure for 2C19 will facilitate computational approaches for predictions of substrate and inhibitor binding to this enzyme.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23118231      PMCID: PMC3531772          DOI: 10.1074/jbc.M112.424895

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

Review 2.  Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.

Authors:  Magnus Ingelman-Sundberg; Sarah C Sim
Journal:  Biochem Biophys Res Commun       Date:  2010-05-21       Impact factor: 3.575

3.  Crystal structure of human cytochrome P450 2D6 with prinomastat bound.

Authors:  An Wang; Uzen Savas; Mei-Hui Hsu; C David Stout; Eric F Johnson
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

4.  Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.

Authors:  Tatyana Zvyaga; Shu-Ying Chang; Cliff Chen; Zheng Yang; Ragini Vuppugalla; Jeremy Hurley; Denise Thorndike; Andrew Wagner; Anjaneya Chimalakonda; A David Rodrigues
Journal:  Drug Metab Dispos       Date:  2012-05-30       Impact factor: 3.922

5.  Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.

Authors:  T S Klose; G C Ibeanu; B I Ghanayem; L G Pedersen; L Li; S D Hall; J A Goldstein
Journal:  Arch Biochem Biophys       Date:  1998-09-15       Impact factor: 4.013

6.  Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer.

Authors:  Patrick M Dansette; Julien Rosi; Gildas Bertho; Daniel Mansuy
Journal:  Chem Res Toxicol       Date:  2011-12-01       Impact factor: 3.739

7.  Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Authors:  Dirk Sibbing; Werner Koch; Daniela Gebhard; Tibor Schuster; Siegmund Braun; Julia Stegherr; Tanja Morath; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati
Journal:  Circulation       Date:  2010-01-18       Impact factor: 29.690

8.  Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity.

Authors:  G C Ibeanu; B I Ghanayem; P Linko; L Li; L G Pederson; J A Goldstein
Journal:  J Biol Chem       Date:  1996-05-24       Impact factor: 5.157

Review 9.  Scaling and assessment of data quality.

Authors:  Philip Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14

10.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21
View more
  26 in total

Review 1.  Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges.

Authors:  Eric F Johnson; J Patrick Connick; James R Reed; Wayne L Backes; Manoj C Desai; Lianhong Xu; D Fernando Estrada; Jennifer S Laurence; Emily E Scott
Journal:  Drug Metab Dispos       Date:  2013-10-15       Impact factor: 3.922

Review 2.  Structural diversity of eukaryotic membrane cytochrome p450s.

Authors:  Eric F Johnson; C David Stout
Journal:  J Biol Chem       Date:  2013-04-30       Impact factor: 5.157

Review 3.  Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame.

Authors:  Sung-Mi Kim; YongQiang Wang; Noushin Nabavi; Yi Liu; Maria Almira Correia
Journal:  Drug Metab Rev       Date:  2016-06-20       Impact factor: 4.518

4.  Crystal Structures of Drug-Metabolizing CYPs.

Authors:  D Fernando Estrada; Amit Kumar; Christopher S Campomizzi; Natalie Jay
Journal:  Methods Mol Biol       Date:  2021

5.  Identification of key licorice constituents which interact with cytochrome P450: evaluation by LC/MS/MS cocktail assay and metabolic profiling.

Authors:  Xue Qiao; Shuai Ji; Si-Wang Yu; Xiong-Hao Lin; Hong-Wei Jin; Yao-Kai Duan; Liang-Ren Zhang; De-An Guo; Min Ye
Journal:  AAPS J       Date:  2013-11-20       Impact factor: 4.009

6.  CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs.

Authors:  Mary Alexandra Schleiff; Samantha Crosby; Madison Blue; Benjamin Mark Schleiff; Gunnar Boysen; Grover Paul Miller
Journal:  Biochem Pharmacol       Date:  2021-11-05       Impact factor: 5.858

7.  A structural snapshot of CYP2B4 in complex with paroxetine provides insights into ligand binding and clusters of conformational states.

Authors:  Manish B Shah; Irina Kufareva; Jaime Pascual; Qinghai Zhang; C David Stout; James R Halpert
Journal:  J Pharmacol Exp Ther       Date:  2013-04-30       Impact factor: 4.030

8.  Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy via screening of a natural product repository.

Authors:  Prashant Joshi; Vinay R Sonawane; Ibidapo S Williams; Glen J P McCann; Linda Gatchie; Rajni Sharma; Naresh Satti; Bhabatosh Chaudhuri; Sandip B Bharate
Journal:  Medchemcomm       Date:  2018-01-08       Impact factor: 3.597

9.  In vitro and in silico studies of interaction of synthetic 2,6,9-trisubstituted purine kinase inhibitors BPA-302, BP-21 and BP-117 with liver drug-metabolizing cytochromes P450

Authors:  A Špičáková; P Kraus; T Gucký; V Kryštof; M Strnad; V Bazgier; M Otyepka; V Kubíčková; M Poruba; Z Rácová; I Zapletalová; P Anzenbacher
Journal:  Physiol Res       Date:  2020-12-31       Impact factor: 1.881

10.  Massively parallel characterization of CYP2C9 variant enzyme activity and abundance.

Authors:  Clara J Amorosi; Melissa A Chiasson; Matthew G McDonald; Lai Hong Wong; Katherine A Sitko; Gabriel Boyle; John P Kowalski; Allan E Rettie; Douglas M Fowler; Maitreya J Dunham
Journal:  Am J Hum Genet       Date:  2021-07-26       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.